Publicaciones (22) Publicaciones de ARTURO LOPEZ CASTEL

2023

  1. Antagonistic roles of canonical and Alternative-RPA in disease-associated tandem CAG repeat instability

    Cell, Vol. 186, Núm. 22, pp. 4898-4919.e25

  2. Natural Compound Boldine Lessens Myotonic Dystrophy Type 1 Phenotypes in DM1 Drosophila Models, Patient-Derived Cell Lines, and HSALR Mice

    International Journal of Molecular Sciences, Vol. 24, Núm. 12

  3. The myotonic dystrophy type 1 drug development pipeline: 2022 edition

    Drug Discovery Today, Vol. 28, Núm. 3

2022

  1. Deciphering the Complex Molecular Pathogenesis of Myotonic Dystrophy Type 1 through Omics Studies

    International Journal of Molecular Sciences, Vol. 23, Núm. 3

  2. Role of miRNAs in muscle atrophy: the myotonic dystrophy paradigm

    MicroRNA: From Bench to Bedside (Elsevier), pp. 331-362

2021

  1. Myotonic dystrophy type 1 drug development: A pipeline toward the market

    Drug Discovery Today, Vol. 26, Núm. 7, pp. 1765-1772

2019

  1. MicroRNA-based therapeutic perspectives in myotonic dystrophy

    International Journal of Molecular Sciences, Vol. 20, Núm. 22

2017

  1. (CCUG)n RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis

    DMM Disease Models and Mechanisms, Vol. 10, Núm. 8, pp. 993-1003

  2. CpG Methylation, a Parent-of-Origin Effect for Maternal-Biased Transmission of Congenital Myotonic Dystrophy

    American Journal of Human Genetics, Vol. 100, Núm. 3, pp. 488-505

2016

  1. Absence of MutSβ leads to the formation of slipped-DNA for CTG/CAG contractions at primate replication forks

    DNA Repair, Vol. 42, pp. 107-118

  2. Six serum miRNAs fail to validate as myotonic dystrophy type 1 biomarkers

    PLoS ONE, Vol. 11, Núm. 2

2014

  1. Development of a Drosophila melanogaster spliceosensor system for in vivo high-throughput screening in myotonic dystrophy type 1

    DMM Disease Models and Mechanisms, Vol. 7, Núm. 11, pp. 1297-1306

2013

  1. 3,4-Dihydroxy- and 3,4-methylenedioxy- phenanthrene-type alkaloids with high selectivity for D2 dopamine receptor

    Bioorganic and Medicinal Chemistry Letters, Vol. 23, Núm. 17, pp. 4824-4827

  2. In vivo strategies for drug discovery in myotonic dystrophy disorders

    Drug Discovery Today: Technologies, Vol. 10, Núm. 1

2011

  1. Expanded CTG repeat demarcates a boundary for abnormal CpG methylation in myotonic dystrophy patient tissues

    Human Molecular Genetics, Vol. 20, Núm. 1, pp. 1-15

  2. Identification of restriction endonucleases sensitive to 5-cytosine methylation at non-CpG sites, including expanded (CAG)n/(CTG)n repeats

    Epigenetics, Vol. 6, Núm. 4, pp. 417-421

  3. Maternal germline-specific effect of DNA ligase I on CTG/CAG instability

    Human Molecular Genetics, Vol. 20, Núm. 11, pp. 2131-2143

  4. Replacement of the myotonic dystrophy type 1 CTG repeat with 'non-CTG repeat' insertions in specific tissues

    Journal of Medical Genetics, Vol. 48, Núm. 7, pp. 438-443

2010

  1. Repeat instability as the basis for human diseases and as a potential target for therapy

    Nature Reviews Molecular Cell Biology, Vol. 11, Núm. 3, pp. 165-170

  2. Tissue-and age-specific DNA replication patterns at the CTG/CAG-expanded human myotonic dystrophy type 1 locus

    Nature Structural and Molecular Biology, Vol. 17, Núm. 9, pp. 1079-1087